secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2024-02-01T23:59:59+00:00
Accession:  0001576885-24-000032
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen appoints Dr. James Doherty as President and Chief Development Officer
----------------------------------------------------------------------------

- Dr. James Doherty appointed President and Chief Development Officer effective Feb 1, 2024, reporting to CEO Daniel O'Connell.
- Doherty previously served as Chief Development Officer at Sage Therapeutics, contributing to two FDA approvals for postpartum depression.
- He will oversee clinical/non-clinical development, CMC, and regulatory functions as Acumen prepares to initiate ALTITUDE-AD study for ACU193.
- Daniel O'Connell's title changes to CEO (previously CEO and President) as Doherty assumes the President role.
- Doherty led Alzheimer's research at AstraZeneca and holds a Ph.D. in Neurobiology from Georgetown University.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688524000032/0001576885-24-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688524000032/abos-20240201.htm
  HTML page:      https://secwatch.observer/filing/0001576885-24-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer